• Owing to a litany of drivers, the days of “green” or “alternative” energy will be terms of the past, replaced by simply “energy” as they are the standard
• GeoSolar Technologies is pioneering the home energy transition with its solar-based, all-electric, high-efficiency home model
• Transitioning homes in the U.S. to GeoSolar’s SmartGreen(TM) homes would be equivalent to removing about 65% of the country’s gas-powered vehicles as far as carbon emissions

“As one era ends, another is just getting started – and we can’t wait to show you what we’ve got coming.” That was a tweet a few weeks ago from Ford New Europe, a message regarding the Company’s transition towards electric vehicles. It’s an appropriate sentiment towards a broader paradigm shift at global scale to say a warm goodbye to legacy technologies, they’ve served us well, while embracing the next generation of innovation that will serve us even better. In the way that Ford is a leader is shepherding in the EV revolution, GeoSolar Technologies (“GST”) is re-imagining homes by using modern technology.

Right now, there are buzzwords that continue to circulate like “EV” and “green energy,” but it is not hard to imagine that the adjectives will be dropped in the coming decades. When every car is powered by electric, won’t they just become “vehicles?” Seems that the adjective will flip to the minority of “gas-powered cars.”

The same is true for “green” or “alternative” energy.” One day it will simply be “energy,” perhaps only with the definer being the source (i.e., solar, wind, hydrogen, etc.). All the evidence points to that day coming. A few examples include:

• President’s Biden’s Inflation Reduction Act earmarked $369 billion in support of implementing alternative energies to reduce emissions
• The government issued a 10-year extension to the solar Investment tax credit
• The International Renewable Energy Agency forecast electricity consumption from renewables will rise from 25% in 2018 to 90% by 2050

Maybe because it is controversial and makes for good media theater, mainstream media tends to focus almost exclusively on EVs and shortcomings with utility-scale solar and wind projects that can be confusing to investors. Fact is, not everything that will be the future is still in the future.

GeoSolar Technologies is a pioneer in the home space with its SmartGreen(TM) Home system, the all-electric home of the future and model of building sustainability. The Company already has several demonstration homes built in its home state of Colorado, a region well known to experience a wide swing of weather conditions, including heavy snow and bitter cold in the winter and hot and sunny summers.

The SmartGreen(TM) model homes delivered some of the best scores ever on the HERS (Home Efficiency Ratings System) Index.

GeoSolar handles every bit of the comprehensive solution from initial analysis to funding and tax credits until installation of the final LED light bulb – which is powered by the new roof-mount photovoltaic solar panel system. Other components include a new geothermal unit for heating and cooling, electric heat pump, “envelope” insulation upgrade, EV charger, advanced whole home purification system, and digital air and energy monitoring application.

The system can be installed during new construction or retrofit into existing structures, typically within only a couple weeks.

Owing to the continuing decrease in prices of products and attractive government incentives, solar has emerged as the most attractive renewable power source for homes as it has the lowest levelized cost of energy (LCOE). LCOE is a measure of average net present cost of electricity generation over a lifetime, allowing for the comparison of different technologies of unequal life spans.

The impact on making this transition as it relates to mitigating climate change is all too often overlooked.

There were an estimated 141.95 million homes in the U.S. in 2021. If all of these homes were converted to SmartGreen(TM) homes, which can help eliminate more than the estimated 12,000-14,000 pounds of carbon per year an average household produces, we could reduce pollution by an estimated 1.9 trillion pounds per year.

To put that into perspective, Statista estimates there were 284.4 million cars in the U.S. in 2022. The U.S. Environmental Protection Agency estimates a typical passenger vehicle emits about 4.6 metric tons of carbon dioxide annually. At 2204.6 pounds per metric ton, that’s 10,141 pounds per vehicle, or 2.95 trillion pounds of carbon emissions. Transitioning homes to SmartGreen(TM) technologies would be like removing 65 percent of the gas-powered cars off the road today.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• SideChannel is committed to creating robust and top-tier cybersecurity programs for small and mid-market businesses (“SMBs”), thus helping them protect vital information and customers
• One of the companies SideChannel has helped achieve this goal is Virgin Voyages, which has expanded its engagement with SideChannel to improve its data privacy efforts with the addition of a virtual chief privacy officer (“vCPO”) from SideChannel
• The move builds on an earlier engagement, bolstering Virgin Voyages’ goal to protect the important information relating to its crew, sailors, and partners

A recent study by IBM Corp. (NYSE: IBM) revealed that the average cost of a data breach in the hospitality industry was $2.94 million in 2022, down from $3.03 million in 2021. This cost, the study highlights, encompasses detection and escalation costs (covering forensic and investigative activities, assessment and audit services, crisis management, and communications to executives and the board), lost business costs (including business disruption and revenue losses from system downtime, cost of lost customers and acquiring new clients, and reputation losses), notification costs, and post-breach response costs (https://ibn.fm/gsq06).

And although the average cost of data breaches within the hospitality industry is lower than in other industries, such as healthcare, financial, pharmaceuticals, technology, energy, retail, and so on, and is, thus, lower than the global average of $4.35 million, based on the findings of the study, the attack vectors that result in the unauthorized access to data remain an ever-present threat.

Unfortunately, according to SideChannel (OTCQB: SDCH) CEO Brian Haugli, “Some companies do not think of cybersecurity and privacy until an event forces them to.” But at that time, it is usually already too late. Preemptive protection is, therefore, recommended, and one company, Virgin Voyages, is doing just that.

A travel brand that delivers epic vacations at sea, Virgin Voyages is focused on proactively protecting its sailors and crew, boosting the cruise and vacation experience, as well as making the workplace safer. The brand, whose Lady ships sail on intercontinental cruises in the Americas and continentally in Europe’s Mediterranean waters, has truly international operations. The international nature of its business, however, creates an environment that is difficult to secure and protect.

In understanding these challenges and the need to protect the data and information of its crew, sailors, and partners, Virgin Voyages recently expanded an earlier engagement with SideChannel to enhance data privacy and protection from ship to shore. As part of the expanded agreement, Virgin Voyages has subscribed to SideChannel’s virtual chief privacy officer (“vCPO”) services, complementing the virtual chief information security officer (“vCISO”) services to which it had earlier subscribed. The vCPO will supplement and augment Virgin Voyages’ current efforts and team (https://ibn.fm/iPvO1).

“I feel very proud that our team’s work earned the trust of the Virgin Voyages crew and persuaded them to work even more closely with us,” said Haugli of the expanded engagement. “Virgin Voyages is propelled to preemptively protect their customers, staff, and all their data. We think that’s something worth celebrating.”

By providing vCPO and vCISO services, SideChannel aims to empower Virgin Voyages to achieve its stated environmental, social, and governance (“ESG”) goal of creating an “Epic Sea Change for All ” by, among others, providing a caring, safe, and secure workplace for its crewmembers (https://ibn.fm/F57LA).

Focused on making cybersecurity simple and accessible for small and mid-market businesses (“SMBs”), SideChannel helps its clients build robust cybersecurity and privacy programs led by expert and experienced vCISOs and vCPOs, who have previously worked as enterprise-level CISOs and CPOs. This way, the company enables client organizations to take control of their security, reduce risk, and ensure cybersecurity and privacy compliance.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• Lexaria’s DIAB-A22-1 animal model study just concluded, highlighting three positive outcomes, including an improvement in general activity, significant reductions in body weight, and improved triglyceride and cholesterol levels
• The study was undertaken by a third-party testing laboratory in Canada involving 24 obese and eight lean rats for a total of 32 male Zucker rats
• The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore its patented DehydraTECH(TM) technology application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more
• With its unique product offering, a growing list of patents, and unique market positioning, Lexaria is becoming a key player in the drug delivery technology space

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the completion of its DIAB-A22-1 animal model study, which explored the potential of the patented DehydraTECH(TM)-processed CBD to treat diabetes. Of note were three positive outcomes, including an improvement in general activity, reductions in body weight, and better triglyceride and cholesterol levels.

The study, undertaken by a leading, third-party testing laboratory in Canada, administered select Lexaria “DehydraTECH-CBD 2.0” formulations with doses of either 30 mg/Kg or 100 mg/Kg of body weight. It involved 24 obese and eight lean rats for a total of 32 male Zucker (“ZDF”) rats. As Lexaria’s first study in the diabetes animal model, the company is encouraged by the positive findings. Moreover, it is confident that the results indicate many prospective benefits worthy of further investigation together, possibly with other drugs that help to control glucose levels directly.

Lexaria set out to explore the therapeutic utility of DehydraTECH-CBD against diabetes in November 2022, on the heels of the success of its clinical studies on hypertension. The company’s management was optimistic that the results from the hypertension study would be replicated in the diabetes study, given that hypertension is twice as frequent in people with diabetes, and hypertensive patients are at greater risk of developing diabetes.

The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore DehydraTECH’s application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more. With DehydraTECH having proven to increase the effectiveness and the way active pharmaceutical ingredients enter the bloodstream, Lexaria is exploring its full potential for improving consumer products. Its efforts have seen the company awarded 28 patents, with more patents pending worldwide.

Diabetes is the 7th largest cause of death in the United States and accounts for an estimated value of $26.7 billion in the global diabetes devices market. Lexaria’s management is hopeful that its current efforts and studies will inch the company closer to taking advantage of this industry’s market potential. In 2021, the global diabetes drug market was estimated at $63.1 billion and is projected to hit $80.65 billion by 2027. With the company’s unique technology, a growing list of patents, and unique market positioning, Lexaria is set to capitalize on this growth and become a leader in the drug delivery technology space.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• A recent medical study found that psychedelic drugs showed promise as a treatment alternative for hard-to-treat depression
• Psychedelics were found to activate a greater number of serotonin 2A receptors then traditional antidepressant drugs, largely because of their ability to penetrated through cells’ fatty outer membranes
• The study reinforces the potential use of psychedelic drugs, and psilocybin in particular, as a treatment methodology for a variety of mental health related conditions
• Silo Pharma, a developmental stage biopharmaceutical company has long focused around merging traditional therapeutics with psychedelic research

In a study carried out between 2013 to 2016, researchers found that 8.1% of American adults aged 20 and over suffered from depression during any given 2-week period, with women nearly twice as likely than men to have had acute depression (https://ibn.fm/ygq4x). Whilst depression has long been treated with a combination of self-help, talking therapies and medicines, studies have previously found anti-depressant drug therapy to not be as effective as traditionally assumed. As a result, a recent study which found that psychedelic drugs could show promise as a therapeutic alternative in treating drug-resistant depression was greeted with some optimism within the sector (https://ibn.fm/cXz8A).

Over the course of the Covid-19 pandemic, rates of depression and anxiety skyrocketed, with many Americans turning to antidepressant medication to help them cope. Whilst 1 in 8 American adults were taking antidepressant drugs prior to the emergence of Covid (https://ibn.fm/FCKnZ), the figure rose by 18.6 percent in 2020 alone. However, a number of research papers have challenged the efficacy of these drugs as well as their assumed actions in the brain. Dr. David Hellerstein, professor of clinical psychiatry at the Columbia University Irving Medical Center addressed the query of whether anti-depressants worked during a recent interview with the New York Times:

“I think they do,” he said. “The best clinical trials and meta-analyses, most of them indicate that there’s some medication effect. [However] I would say it’s less than we would like it to be.”

Alternative treatments for depression have emerged that attempted to help the brain create new connections more efficiently – most notably ketamine and psychedelic therapy; initial findings have found these alternative treatments to be about as effective as antidepressants, improving depression in roughly 60 percent of the people who try them. It is precisely this issue which Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, has set out to tackle.

Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease and other rare neurological disorders. The company has recently entered into a number of studies designed to develop innovative solutions for previously underserved conditions. In doing so, the company recently entered into an agreement with Columbia University, granting it an option to license a number of assets under development including a prophylactic treatment for stress-induced disorders and PTSD.

Psychedelics such as psilocybin, the active compound found in magic mushrooms, have been known to plug into a structure called the serotonin 2 receptor, which bids the chemical messenger serotonin. Traditionally, antidepressants are designed to increase the levels of serotonin, so that when more of the serotonin neurotransmitters is sent to other parts of the brain, the person feels relief from depression. What the study found was that psychedelics were increasingly able to access receptors inside cells which standard antidepressants could not normally affect, thereby increasing the level of serotonin secreted within the brain – largely because of their ability to pass through cells’ fatty outer membranes to reach the additional receptors within.

The study now provides medical substance to a theory which has long been held by indigenous populations around the world – that the use of psychedelics, and psilocybin in particular could have beneficial effects for a variety of mental health related conditions. Although psilocybin was classified as a “breakthrough therapy” in treatment for severe depression by the U.S. Food and Drug Administration as far back as 2018 (https://ibn.fm/tXJM5), findings within the recent research report may now serve to support the development of psychedelics as a more mainstream medical treatment alternative for drug-resistant depression.

With psilocybin and psychedelic-based therapeutic treatment increasingly gaining favour amongst the medical community and with a rising prevalence of depression and mental disorders within modern society, forecasts have now projected the psychedelic drugs market to swell to a value of $6.8 billion annual by 2027, representing a CAGR of 16.3% within the forecast period of 2020 to 2027 (https://ibn.fm/mQJTH). As a frontrunner in the sector and with a number of research and drug developmental initiatives under way, Silo Pharma find themselves well positioned to capitalize on the growth of the sector going forward.

For more information, visit the company’s website at www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• BiondVax is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, primarily for the treatment of infectious and autoimmune diseases
• The company is led by CEO Amir Reichman, with over 20 years of international experience as a biopharma expert
• Amir took company reins in 2021 and pivoted the mission and vision including diversifying risks
• With new focus and opportunity, BiondVax now developing an innovative alpaca-derived nanosized antibody (“NanoAb”) pipeline
• BiondVax is aggressively advancing new NanoAb therapeutic and prophylactic technologies owing to exclusive collaborations, previous pharma development experience and a state-of-the-art GMP manufacturing facility

Leveraging top-tier pharmaceutical industry leadership, extensive drug development expertise, a GMP biologics manufacturing facility, and strategic collaborations with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen (“UMG”), BiondVax Pharmaceuticals (NASDAQ: BVXV) is aggressively advancing development of a pipeline of diversified, commercially viable “NanoAb” products and platforms. The Jerusalem, Israel-headquartered biopharmaceutical company is initially focused on an innovative inhaled nanosized antibody treatment for COVID.

“Overall, the NanoAb platform is an incredible opportunity for BiondVax,” said BiondVax CEO Amir Reichman following the late 2021 signing of definitive agreements with MPI and UMG to develop and commercialize the innovative anti-COVID-19 NanoAb therapy (https://ibn.fm/ZlrYX). “It will serve as a basis for an exciting new pipeline of commercially attractive products to address unmet therapeutic needs of diseases such as psoriasis, psoriatic arthritis, asthma, and macular degeneration.”

The definitive agreements came only a few months after Amir’s appointment as CEO. Amir had previously served as Head of Global Vaccines Engineering, Core Technologies, and Asset Management at GSK Vaccines, headquartered in Belgium. Prior to taking up this role, he had served as Senior Director of Global Supply Chain Performance and Capabilities at the same company. Collectively, Amir has more than 20 years of international hands-on experience as a bio-pharma expert (https://ibn.fm/3XzzO). Leveraging this expertise, he made a few strategic changes to BiondVax when he took over as CEO on March 2, 2021.

“The first thing I have done as the new CEO, together with our Board of Directors, was to define a new mission and vision for BiondVax. Our new mission reflects an aspiration to focus on infectious diseases, which leverages BiondVax’s core competencies, while ensuring diversification of our corporate risks through the establishment of a new, broad product and platform pipeline,” Amir wrote in his first letter to shareholders (https://ibn.fm/JdTFq).

Although Amir and the board sought to diversify and mitigate risk by implementing strategic changes, the company still benefitted from its previous focus on developing the M-001 universal influenza vaccine candidate. Up until that point seven Phase 1/2 and 2 clinical trials conducted in Europe, Israel, and the USA, were completed, each with promising results. The success of these trials had guided the company’s execution of a pivotal phase 3 clinical trial in seven countries. Conducted between 2018 and 2020, the trial involved 12,400 participants and was completed on time and within budget (https://ibn.fm/tIbbo).

In many compelling ways, BiondVax punches well above its weight compared to biopharma companies of similar market cap: BiondVax gained extensive drug development expertise in these trials which is expected to be invaluable in the development and commercialization of the NanoAb pipeline. The company plans to undertake the first-in-human phase 1/2a clinical trial evaluating its inhaled anti-COVID-19 NanoAb therapy later this year. This rapid development path hinges not only on the expertise of its workforce and experience gained from the development of M-001 but also on its capabilities in biological drug development and manufacturing.

In 2018, BiondVax completed a 20,000-square-foot campus in Jerusalem that includes offices, laboratories, and a GMP biologics manufacturing facility, according to Amir (https://ibn.fm/7fdYz). The facility provides BiondVax with state-of-the-art GMP-ready manufacturing capabilities, enabling the company to handle pharmaceutical product development and manufacturing. As a result and following the closing of the agreements with its strategic collaborators, MPI and UMG, BiondVax’s strong team is putting the facility to use, mass producing the NanoAbs through recombinant protein manufacturing. These early batches have been used in a highly successful preclinical test of its inhaled COVID-19 NanoAb (https://ibn.fm/u5I73 and https://ibn.fm/ImvSC), and future batches are planned for the first-in-human phase 1/2a clinical trial planned for later this year.

BiondVax believes that its extensive drug development experience, experienced leadership, manufacturing capabilities, and product and platform pipeline ideally position it for in-licensing, acquisitions, and joint ventures, as well as rapid clinical development and manufacturing of new therapeutic and prophylactic technologies, beginning with the inhaled anti-COVID-19 NanoAb candidate.

By leveraging expertise, experience and collaborations, BiondVax aims to disrupt high value large market opportunities with its pipeline of innovative NanoAb therapeutics.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• McEwen Mining subsidiary McEwen Copper has been gaining increased financial support as it develops a major copper mine opportunity in Argentina described as one of the 10 largest undeveloped deposits in the world
• Mining giant Rio Tinto’s venture Nuton LLC has boosted last year’s $25 million investment into McEwen Copper with a new $30 million addition, all on top of the recent Stellantis investment of approximately $155 million
• The project in Argentina’s San Juan province benefits from a mining-friendly government and population
• The demand for copper is expected to continue to grow as a result of its importance to green energy transition efforts and ongoing challenges the metal’s supply stream faces

The strength of metals explorer McEwen Copper’s profile and of its parent company McEwen Mining (NYSE: MUX) (TSX: MUX) was further demonstrated recently by a second investment of $30 million, at $18.75 per share  boost to an investment made by mining and metals giant Rio Tinto’s venture Nuton LLC. Nuton first invested $25 million last August, at $10 per share. as part of a private placement to help fund McEwen Copper’s development of its Los Azules Project in Argentina’s mining friendly province of San Juan (https://ibn.fm/cAKBx).

The Nuton investment is in addition to the recently announced closure of an  investment by automotive multinational Stellantis, the world’s 4th largest automobile manufacturer, of approximately $155 million.

McEwen Copper Inc. holds 100 percent interest in the Los Azules copper project and McEwen Mining owns about 52 percent of McEwen Copper, Nuton and Stellantis each own 14.2% and Rob McEwen owns 13.8%.

“We are extremely pleased to have Nuton’s strong continued participation in McEwen Copper. Together we are exploring new technologies that save energy, water, time and capital in the pursuit of delivering green copper to Argentina and the world, a product that will contribute to the electrification of transportation and the protection of our atmosphere,” McEwen Copper CEO Rob McEwen stated (https://ibn.fm/WfNmr).

Last year MINING.COM, and its sister company Miningintelligence, included the Los Azules Project as being among the 10 largest undeveloped copper deposits in the world, noting its current copper resources at an estimated 10.2 billion pounds at a grade of 0.48 percent Cu (Indicated category) and an additional 19.3 billion pounds at a grade of 0.33 percent Cu (Inferred category) (https://ibn.fm/TlMjj).

Copper is regarded as a bellwether metal signaling the direction of the global economy, and while prices have remained below 2021’s peak their northward trend has generated excitement among market watchers this year (https://ibn.fm/ssDgC). The metal is vital for the transition to green energy that world governments and climate change activists have been seeking, and demand for it is expected to continue climbing even as the supply chain faces challenges that new productivity in Argentina could help to alleviate (https://ibn.fm/1qfKN).

Los Azules has been popular with the local government because of the pioneering efforts to make mine development more environmentally friendly and because of the employment opportunities it provides hundreds of workers in the region (https://ibn.fm/9vXUc).

McEwen Copper states it is well-funded into 2024. Updated Preliminary Economic Assessment (“PEA”) expected in early Q2 2023 and an IPO in late H2 or early 2024.

For more information, visit the company’s website at www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

• Massachusetts-headquartered cybersecurity services and technology provider SideChannel Inc. is building its operational model on contracting out its employees’ expertise as “virtual” chief information security officers (vCISOs) to companies that can’t afford to staff their own CISOs
• SideChannel’s CEO and CFO recently addressed the company’s history, expertise and strategies for the future in an Investor Day webcast that is now being rebroadcast on the company’s YouTube channel
• The webcast noted that SideChannel is tapping into an underserved market of mid-market clients whose needs for cybersecurity mirror those of larger-budget companies who can afford to employ their own CISOs
• During 2022, about 200,000 cyber attacks were reported at an average cost of $4.5 million per company to recover when a breach occurred, according to the webcast

An Investor Day webcast event hosted by cybersecurity services and technology provider SideChannel (OTCQB: SDCH) provided insights on the company in a virtual meeting place that addressed the company’s history, its products, its financial position, its strategies for the future and introduced some of officers and board members for those investigating SideChannel’s potential.

The live webcast took place last month but video of the event now is available on the company’s YouTube channel, showcasing CEO Brian Haugli’s efforts to engage the investing community in an open and cost-effective manner while addressing the importance of safeguarding SMB business computer network operations.

“We see Fortune 500s having easy access to large (cybersecurity) providers but, really, the middle market is over a million companies, and who’s working with them?” Haugli said in introducing the forum (https://ibn.fm/0UVzj). “That’s what we set out to do with SideChannel. … I joke about this — there’s only 2,000 companies in the Fortune 2000. Who’s working with everyone else? It’s an untapped market.”

SideChannel’s key service is providing companies who don’t have their own chief information security officers (“CISOs”) to lead their cybersecurity strategy with SideChannel’s outsourced expertise in the form of contract “virtual” chief information security officers (vCISOs) for hire. The company also launched a microsegmentation security product last September that it brands Enclave that it considers competitive because of its lower price point and ease of use, as well as a managed service option not offered by other companies.

“Our revenue is really built on relationships,” CFO Ryan Polk added during his portion of the webcast. “The vast majority of the work that we do for our clients has an ongoing nature to it. … We are retaining about 73 percent on a trailing 12-month basis of the revenue that we generated one year ago. … Revenue retention of 70-plus percent, we think, is a clear indication that our customers like what we have done for them in the past and would like for us to continue doing that for them in the future.”

Haugli noted the importance he places on responding to the needs of an underserved market and the benefits that may result for his company, commenting that the “mid-market” companies whose financial budgets may not be large enough to allow them to efficiently maintain full-time chief information security officers still collectively account for $8 trillion in revenues.

“The same risks exist at enterprises that exist at mid-market and vice versa,” Haugli said. “We’re seeing attacks increase. We’re seeing the costs of these attacks increase over time. And we’re seeing them change.”

Security Magazine recently noted a report by Check Point Research stating cyber attacks increased 38 percent globally during 2022, with North America and Latin America at the leading edge of geo-political regions experiencing the attacks — 52 percent and 29 percent, respectively (https://ibn.fm/NF0XI).

SideChannel’s webcast stated some 200,000 cyber attacks occurred in 2022 and that the average cost of recovering from a breach was $4.5 million per company.

“Where we step in is, obviously, identifying and knowing what can slow (the attackers) down, what can stop them, (and) what can be built at an organization that allows you to feel much better about your cybersecurity posture in addressing those risks and addressing regulatory concerns, and addressing the questions from your board or your C-suite — being able to put your customers’ concerns at ease,” Haugli said.

The company’s most recent financial statement shows the company brought in $5.3 million total revenue during the previous 12 months, with 26 percent sequential quarterly growth and 48 percent YOY quarterly growth, underlining Polk’s assertion that the company has tapped into a new market.

In a video that contained testimonials by SideChannel’s employees, vCISO Stephen Dye talked about his experience working with a federal contractor in Virginia and the value he finds now working with SideChannel’s clients.

“Customers that I work with are ones that really do need a security program and they’ve recognized that they need it and (that) their budgets don’t allow for that full-time CISO, which of course is our business model,” Dye said. “There’s high expectations on their behalf and of course we’re of that caliber where we can deliver to those expectations, so it is a pleasure to work with these people. … They appreciate the advice and input that we give regarding choice of tools and other third-party services to actually make the security program work.”

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• The global antihypertensive drugs market was valued at around $20.5 billion in 2021 and is expected to reach $39.5 billion by 2030, growing at a CAGR of 2.95%
• Lexaria’s patented DehydraTECH(TM) technology is designed to formulate and deliver lipophilic drugs and active pharmaceutical ingredients (“APIs”), increasing effectiveness and improving how drugs are delivered into the bloodstream
• DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, or oral suspensions
• Lexaria is continuing to evaluate the results of its HYPER-H21-4 human clinical study and will report additional findings as they become available

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced additional findings from its human clinical study HYPER-H21-4, demonstrating a potentially novel mechanism of action of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) capsule formulation in reducing blood pressure. The FDA lays out clear guidelines for sponsors seeking to develop new anti-hypertension drugs, specifically defining the need for medications that offer complimentary modes of action. Lexaria believes that its latest results, detailed in the peer-reviewed and published in the journal “Biomedicine and Pharmacotherapy,” may support DehydraTECH-CBD qualification within the FDA guidelines (https://ibn.fm/aMeMc).

The global antihypertensive drugs market was valued at around $20.5 billion in 2021. The market is expected to grow at a CAGR of 2.95% between 2022 and 2030, resulting in a value of $39.5 billion, as a result of a worldwide increase in the number of hypertension cases. Hypertension is a common but serious medical condition, with more than 1.13 billion people suffering, according to the World Health Organization (“WHO”) (https://ibn.fm/NYLKJ).

Lexaria’s DehydraTECH is designed to formulate and deliver lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (“APIs”). DehydraTECH increases the effectiveness and improves the way APIs enter the bloodstream. The benefits of consuming a DehydraTECH-enabled drug or product include:

• Speed up in delivery time – with the effects felt by the consumer in minutes versus hours
• Increased bioavailability – with more delivery of the drug into the bloodstream than traditional methods
• Increased brain absorption – animal testing suggests significant improvement in the quality of the drug delivered across the blood-brain barrier
• Improved drug potency – more of the ingested product is made available to the body, with lower dosages required to achieve desired effects
• Reduction in drug administration costs – lower dosages mean lower overall drug costs

Animal studies of DehydraTECH have demonstrated the ability to elevate the quantity of the drug delivered across the blood-brain barrier by as much as 1,900 percent. Not only did those studies support additional patent applications, the results could be impactful to its hypertension program given that human blood pressure is in large part controlled by the central nervous system. The technology is also being evaluated for additional orally administered API’s, including  cannabinoids,  nicotine, and more. Lexaria currently possesses 28 granted patents, with many more pending worldwide.

Lexaria’s technology is best thought of as a foundation that providers of drugs and consumer supplements can utilize to improve the effectiveness of their existing or planned new offerings. DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, or oral suspensions.

Lexaria continues to study endpoint analyses as described in the complete study protocol for HYPER-H21-4, and any relevant material findings will be reported as they become available.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

The 9th annual Blockchain Africa Conference 2023 is a highly anticipated event for those in the tech and finance industries. This year’s conference will take place on March 16 – 17 in Johannesburg, South Africa and will bring together experts from all over the world to discuss the latest trends and developments in blockchain technology.

Blockchain technology is one of the most exciting innovations of recent times and has the potential to revolutionize the way we conduct financial transactions, store and secure data, and manage digital identities. The Blockchain Africa Conference 2023 is a perfect opportunity to learn about these advancements and how they can benefit businesses and individuals alike.

The conference will feature a range of keynote speakers, panel discussions and fireside chats, covering topics such as the Why ReFi is the Future of Web3, Financial Inclusion Around the World, The Flight to Safety- Why a Crypto Bank is More Secure than Blockchain, and Evolution of Digital Assets Custody Blockchain: An End to Systemic Corruption. Attendees will also have the opportunity to network with industry leaders and experts, and learn about the latest projects and products in the blockchain space.

One of the key themes of this year’s conference is the role of blockchain in financial inclusion. Blockchain technology has the potential to bring financial services to the billions of people around the world who are currently excluded from traditional banking and finance systems. By enabling secure, fast and affordable financial transactions, blockchain technology can help to create new opportunities for economic growth and empowerment.

Another important theme of the conference is the potential of blockchain to create new opportunities for entrepreneurship and innovation. Many experts believe that blockchain technology will be a key driver of the next wave of innovation and will help to create new business models and revenue streams for companies.

In addition to this year’s conference, will also feature a workshop, hosted by Celo “Build Together and Prosper”. Celo is the carbon-negative, mobile-first, EVM-compatible blockchain ecosystem leading a thriving new digital economy for all. Find out more about the workshop here.

The 9th annual Blockchain Africa 2023 is a must-attend event for anyone interested in the future of blockchain technology and its impact on business and society. Whether you are a developer, entrepreneur, investor, or simply curious about this exciting new technology, the conference offers a valuable opportunity to learn, network, and gain inspiration. So make sure to register now and be a part of the conversation that will shape the future of blockchain in Africa and beyond. Register Now as Tickets are Limited! The event is offering a 35% discount on the In-Person Standard Tickets and FREE Live-Streaming Tickets to all our subscribers! All In-Person Tickets include live-streaming access. (T &C: valid for a limited period). Apply the following promotional code to receive 35% discount on In-Person Standard Tickets: BAC23-35%STD-Odash Register Now

For additional information, visit https://ibn.fm/9BDkm.

• RNG is a carbon-neutral alternative to natural gas that is compatible with existing pipeline infrastructure
• RNG is considered carbon-negative because it is produced from organic materials that otherwise decompose and generate methane emissions
• EverGen leads RNG adoption in Canada by acquiring, developing, and managing portfolio of RNG and waste-to-energy projects
• EVGIF aims to develop a cross-country RNG platform of 20+ facilities within five years, starting with British Columbia, Alberta, and Ontario
• EverGen management predicts RNG opportunity to exceed C$16 billion for RNG producers

EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF) is focused on achieving a Net-Zero future by leveraging the power of renewable natural gas (“RNG”) – a carbon-neutral alternative to natural gas that is compatible with existing pipeline infrastructure.

RNG is carbon-negative since it is produced from organic materials that would otherwise decompose and generate methane emissions. By preventing the release of greenhouse gasses into the atmosphere, RNG has the potential to make a more substantial impact than other fossil fuel alternatives like solar panels and wind turbines.

Besides preventing the release of methane into the atmosphere, the production of RNG can increase crop yields by creating digestate – a nutrient-rich fertilizer produced as a byproduct of the agricultural digestion process. Further, RNG production from waste does not require large tracts of land or other natural resources and helps protect areas by diverting waste from landfills.

“We need to deal with our waste, as humans,” said EverGen CEO Chase Edgelow, in a recent feature on RNG by the World Economic Forum (https://ibn.fm/yxH0b). “We need waste infrastructure. But we also want to decrease carbon emissions. So why would we let the energy from that waste infrastructure go straight into the atmosphere and go to waste?”

EVGIF leads RNG adoption in Canada by acquiring, developing, and managing a portfolio of RNG and waste-to-energy projects, while planning to develop an RNG platform of 20+ facilities within five years. The company currently owns and operates five RNG and/or organic processing facilities across Canada. These include Fraser Valley Biogas, Sea to Sky Soils, and Net Zero Waste Abbotsford in British Columbia, a 67% ownership stake in GrowTEC in Alberta, and a 50% stake in Project Radius located in Ontario. RNG generated from several of these projects, including Fraser Valley Biogas, Net Zero Waste Abbotsford, and GrowTEC, is bought by FortisBC through a long-term offtake agreement.

Canada is not alone in its push for RNG adoption. The United States and eighteen European Union nations are investing in RNG projects in an effort to reduce emissions and promote sustainability (https://ibn.fm/MK2vG). Further, several North American gas utilities have established targets to incorporate RNG into their natural gas supplies that range from 5-15%. EverGen’s management recognizes this transition as a potential opportunity worth over C$16 billion for RNG producers.

EverGen Infrastructure Corp. is a well-established independent renewable energy producer that aims to develop RNG infrastructure throughout Canada. With a strong focus on sustainability and achieving a Net Zero future, the company is quickly emerging as a leader in the industry that is committed to powering a carbon-free future with renewable energy sources.

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF